

Table S3. IRs, crude and adjusted HRs, and 95% CIs for HRs, of hospital-admitted ischemic stroke between T2D patients with and without GLP-1RAs grouped by cumulative doses during the study period in all GLP-1RAs and each type of GLP-1RAs

Variable	Person	Event	Person-Year	IR	Crude		Adjusted	
		n = 113		1,000 person-years	HR (95% CI)	P-value	HR (95% CI)	P-value
GLP-1RAs non-users	6,534	67	22,643	2.96	1 (Reference)		1 (Reference)	
GLP-1RAs users								
1-823 mg	1,643	14	4,643	3.02	1.00 (0.56, 1.78)	0.9957	1.02 (0.57, 1.82)	0.9399
824-1,784 mg	1,626	15	3,788	3.96	1.36 (0.77, 2.39)	0.2851	1.42 (0.81, 2.50)	0.2212
1,785-6047 mg	1,625	5	5,790	0.86	0.29 (0.12, 0.73)	0.0080	0.30 (0.12, 0.75)	0.0102
> 6047 mg	1,640	12	8,690	1.38	0.47 (0.25, 0.87)	0.0166	0.46 (0.25, 0.85)	0.0127
<i>Liraglutide</i>								
1-2,519 mg	686	7	3,118	2.25	0.78 (0.36, 1.71)	0.5390	0.75 (0.34, 1.63)	0.4616
2,520-6,803 mg	702	5	3,287	1.52	0.53 (0.21, 1.31)	0.1683	0.56 (0.22, 1.39)	0.2104
6,804-14,183 mg	696	4	3,470	1.15	0.40 (0.14, 1.09)	0.0740	0.41 (0.15, 1.12)	0.0809
> 14,183 mg	695	7	3,887	1.80	0.61 (0.28, 1.34)	0.2167	0.58 (0.26, 1.27)	0.1698
<i>Dulaglutide</i>								
1-423 mg	890	7	1,983	3.53	1.26 (0.57, 2.75)	0.5674	1.31 (0.59, 2.87)	0.5059
424-1,175 mg	841	3	1,953	1.54	0.55 (0.17, 1.74)	0.3061	0.62 (0.19, 1.97)	0.4166
1,176-1,754 mg	929	9	3,760	4.91	1.88 (0.89, 3.98)	0.0998	2.10 (0.98, 4.47)	0.0549
> 1,754 mg	882			0.47	0.16 (0.02, 1.16)	0.0697	0.15 (0.02, 1.12)	0.0647
<i>Exenatide</i>								
1-175 mg	281	3	1,617	1.86	0.58 (0.18, 1.86)	0.3596	0.63 (0.19, 2.02)	0.4347

<i>176-717 mg</i>	284	6	1,635	3.67	1.15 (0.50, 2.68)	0.7397	1.26 (0.54, 2.96)	0.5952
<i>718-2,359 mg</i>	282	5	3,405	2.44	0.76 (0.28, 2.11)	0.6016	0.98 (0.35, 2.74)	0.9701
<i>> 2,359 mg</i>	283			0.57	0.17 (0.02, 1.26)	0.0829	0.17 (0.02, 1.21)	0.0769

*: Adjusted for gender, age, each of comorbidities, and each of concomitant medications listed in Table 1.

Abbreviation: CI, Confidence Interval; GLP-1RAs, Glucagon Like Peptide-1 Receptor Agonists; HR, Hazard Ratio; IR, Incidence Rate; T2D, Type 2 Diabetes.